Opdivo

News

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck bags adjuvant okay for Keytruda in melanoma

Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.

News

Opdivo and Keytruda approved in new lung cancer uses

The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), after green-lighting Bristol-Myers Squibb’s (BMS)

News

Merck & Co's Keytruda shows potential in head and neck cance...

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.

News

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

News